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Importance: Emerging evidence suggests a role for sleep in contributing to the progression of Alzheimer disease 
(AD), but the features of sleep that mediate this remain poorly characterized. Slow wave sleep (SWS) is the stage 
during which synaptic activity is minimal and clearance of neuronal metabolites is high, making it an ideal state to 
regulate levels of amyloid beta (Aβ).  
Objective: To examine relationships between concentrations of Aβ42 in the cerebrospinal fluid (CSF) and measures 
of SWS duration, slow wave activity (SWA) and SWS continuity in cognitively normal elderly subjects. 
Design: We analyzed Aβ42, P-Tau and, T-Tau in CSF by ELISA. Nocturnal polysomnography (NPSG) was 
performed within 6.7±7.5 months of the lumbar puncture and analyzed for SWS duration, total SWA, SWA in 
NREM cycles 1-4, and mean SWS bout length. 
Setting: Community dwelling elderly subjects were evaluated at the NYU Center for Brain Health and received 
NPSG’s at the NYU Sleep Disorders Center.  
Participants: 36 elderly subjects (age 66.8±8.2) with normal cognition and without significant sleep disordered 
breathing  
Main Outcome and Measure: Correlations and linear regression analyses were used to assess for associations 
between CSF Aβ42 levels and measures of SWS controlling for potential confounders. Resulting models were 
compared to each other using ordinary least squared linear regression analysis. Additionally, the participant sample 
was dichotomized into ‘high’ and ‘low Aβ42’ groups to compare SWS bout length using survival analyses. 
Results: Total sleep time, time spent in NREM1, NREM2 or REM was not correlated with CSF Aβ42. A significant 
inverse correlation was found between CSF Aβ42 levels, SWS duration and other SWS characteristics. Collectively, 
total SWA in the frontal lead was the best predictor of reduced CSF Aβ42 levels when controlling for age and 
ApoE4 status. 
Conclusion and Relevance: In cognitively normal elderly, reduced and fragmented SWS is associated with 






 3. Text 
 
INTRODUCTION: 
The ‘Amyloid Cascade Hypothesis’ posits that the deposition of amyloid beta (Aβ) in the brain is the initiating 
pathological event in Alzheimer’s disease (AD) (1). Several studies have provided evidence that Aβ dynamics are 
influenced by the sleep-wake cycle. In transgenic mice, soluble Aβ levels are higher in the interstitial fluid during 
wakefulness and lower during sleep, while sleep deprivation increases Aβ concentrations and accelerates plaque 
deposition (2). In humans, cerebrospinal fluid (CSF) Aβ42 also exhibits a diurnal pattern, with the lowest levels 
occurring in the morning sampling (3). This physiological morning decrease in CSF Aβ42 is abolished by total sleep 
deprivation (4).  All these findings suggest that sleep may play a unique role in AD by resetting soluble Aβ42 to 
lower levels, however, the precise regulation of this diurnal pattern is not well understood.  
Aβ production is thought to be neuronal activity-dependent, and plaque deposition preferentially targets brain 
regions with high neuronal and large-scale synchronous activity (5). During sleep, the brain remains predominantly 
active with preservation of cortico-cortical connectivity during light sleep, i.e. non-REM (NREM) sleep stages 1-2.   
However, there is a reduction in fronto-parietal connectivity that occurs with increasing depth of sleep, to the point 
of being significantly reduced at deep sleep, i.e. slow wave sleep (SWS) or NREM stage 3 (NREM3) (6). During 
REM sleep, brain activation becomes more frequent (7). In this study, we assessed the effect of SWS characteristics 
on morning CSF Aβ42 levels in a group of cognitively normal elderly. We hypothesized that conserved SWS would 
be associated with low morning CSF Aβ42 levels, while disrupted SWS would be associated with high morning 
Aβ42 levels. Given that reduced CSF Aβ42 levels and SWS duration can be associated with advanced age, the 
ApoE4 allele, male gender and lower number of years of education, we also tested the extent to which the variation 




Study Design and Participants 
Among a pool of elderly participating in NIH-supported longitudinal studies, this study included a sub-set of 41 
subjects that agreed to undergo nocturnal polysomnography (NPSG). Subjects were recruited from multiple 
community sources in NYC as previously described (8).  Individuals with medical conditions that could affect brain 
structure or function were excluded.  
Procedures 
Subjects received a clinical standardized diagnostic assessment part of the Uniform Data Set II at the NYU Center 
for Brain Health (9). In addition, subjects had laboratory examinations and underwent a structural MRI, a morning 
lumbar puncture (LP) and a NPSG. All subjects were diagnosed as cognitively normal (Clinical Dementia Rating 
[CDR]=0). ApoE4 genotype was determined using the Polymerase Chain Reaction (11).  CSF samples were 
processed as described previously (8). CSF was analyzed for Aβ42, phosphorylated tau at threonine181 (P-tau) and 
total tau (T-Tau) using ELISA kits (Fujirebo, Ghent, Belgium)(12). 
All subjects received structural volumetric MRI scans as part of the parent NIH grants on a 1.5T (GE, USA) or 3T 
(Siemens, Germany) system using standardized procedures (13;14). These scans were obtained to rule out MRI 
evidence of intracranial mass and white matter disease prior to performing the LPs. Age-related atrophy in the 
medial prefrontal cortex (mPFC) cortex has been associated with reduced slow wave activity (SWA) in older adults 
(15). Because atrophy mediates SWS disruption, we measured cortical volumes from MPRAGE sequences using the 
FreeSurfer toolkit (16). We then computed gray matter volumes to create an mPFC region of interest (ROI) using 
the following bilateral ROIs: caudal anterior cingulate cortex, medial orbitofrontal cortex, rostral anterior cingulate 
cortex and superior frontal gyrus (23). Resulting ROIs were adjusted (residualized) to their intracranial volume 
using linear regression.  
Sleep recordings were performed overnight at the NYUSDC as previously described (17). They consisted of six 
EEG channels (F3, F4, C3, C4, O1 and O2), two electro-oculographic (EOG) leads and one chin electromyographic 
channel. Visual scoring of recordings, total sleep time (TST) and sleep stage duration in minutes were determined 
according to AASM criteria (17). Respiratory events were scored using AASM criteria as described previously (8).  
AHI4% was defined as the sum of all apneas and hypopneas with ≥4% desaturation divided by TST in hours. AHI-
all was defined as the sum of apneas and hypopneas (3% or arousal) divided by TST in hours. 
Sleep studies were first scored in 30-second epochs (17). NREM-REM cycles were defined according to the criteria 
of  Feinberg and Floyd (18) starting with NREM2 and containing at least 15 minutes of NREM2 or NREM3 
followed by a REM episode of at least 5 minutes. EEG signals, acquired with a sampling frequency of 256Hz, were 
then segmented into 5-second epochs. Power spectra of artifact-free epochs were computed using the Fast-Fourier 
Transform and matched with the 5-second sleep scores. SWA was calculated using the average power density in the 
0.5-4.0 Hz range of F4, C3 and O2 full-night EEG recordings. Changes in SWA were evaluated using areas under 
the curve (AUC) for each NREM sleep cycle and for the full night. To account for individual differences in the 
occurrence and duration of sleep cycles, NREM episodes were first subdivided into 24 equal segments, and then 
averaged in each segment (19). Where appropriate, group comparisons of SWS characteristics were performed using 
the median CSF Aβ42 value to divide the sample into two equal sized (‘high’ and ‘low’) Aβ42 groups.  
Outcome measures used in statistical analyses were age, gender, ApoE4 status, years of education, CSF biomarkers 
(Aβ42, P-Tau, T-Tau), SWS duration, percent of TST spent in SWS (%SWS), SWA full night, mean SWS bout 
length, SWA in NREM cycles 1-4 and mPFC.   
 
Statistical Analyses 
Logarithm transformation was applied to normalize right skewed variables (CSF Aβ42, SWA in F4, C3 and O2) 
prior to analysis. We first assessed the effect of SWS duration and other SWS characteristics on morning CSF Aβ42 
levels in the entire group using correlation analyses. We then used ordinary least squared (OLS) linear regression to 
evaluate the associations between the SWS characteristic with the highest correlation coefficient and CSF Aβ42, 
using Aβ42 as the dependent variable.  Age, ApoE4 status, sex and years of education were included as covariates 
only if they improved the R2 and adjusted R2 for the model. The best fitting model was then replicated with each of 
the other SWS characteristics. On a final step we compared the resulting models looking at percent increase in R2 
for each model. 
Finally, we analyzed SWS bout length after dichotomizing the sample into ‘low Aβ42’ and ‘high Aβ42’ groups 
using the median CSF Aβ42 (536.9 pg/ml). Survival analysis was used to estimate the time of interest in the 
duration from the onset of sleep (or a specific stage thereof) to the transition to wake (or to some other stage). The 
period between the onset of sleep and a terminating transition was used to define a ‘run’. ‘SWS runs’ were defined 
as consecutive epochs of SWS bounded by either NREM1, NREM2, REM or wake. Using the standard techniques 
of survival analysis, a bootstrap-based analysis that accounted for the number of runs contributed by each subject 
was performed to determine a cumulative duration probability distribution for SWS. In order to remain consistent 
across all subjects and, at the same time, retain a sufficient number of data points, SWS runs were randomly 
sampled up to the median number in the cohort. Log rank tests were used to compare both groups on the curves 
derived from the sampling procedure. This procedure was repeated 1,000 times. At each step of the iteration, a p 
value was estimated from the history of prior p values, yielding an increasingly stable result as the number of 
iterations increased.  
 
RESULTS: 
Healthy, cognitively normal group with low overall risk for AD: 
41 eligible participants completed all study procedures. Five were excluded due to moderate to severe SDB 
(AHI4%≥15) (3 subjects), fragmented sleep with TST <3 hours (1 subject) and alcohol consumption prior to the 
NPSG (1 subject).  Demographic, cognitive, and health characteristics of the remaining 36 participants are shown in 
Table 1 (‘Global’). Overall, it was a sample of mostly non-obese (BMI 25.8±3.7 kg/m2), highly educated (16.3±2.1 
years of education), elderly (age 66.9±8.3 years), in good general health. Table 1 displays mean values of CSF 
Aβ42, T-Tau, and P-Tau levels.  Overall, it was a healthy group with low overall risk for AD.   
 
Sleep characteristics: 
Table 3 summarizes sleep architecture characteristics. Only 5 subjects had mild SDB (AHI4%=5-14.99), while the 
majority of subjects had normal breathing during sleep (AHI4% <5). Epworth sleepiness scores did not suggest the 
presence of daytime sleepiness in our sample (value 6.4±3.9). Table 2 shows the SWS characteristics of our sample.  
SWS duration was inversely correlated with age (r=-0.36, p<0.05) and WASO (r=-0.51, p<0.05), but was not 
associated with BMI; AHI4%, AHIall, mean O2Sat during sleep, TST, NREM1, NREM2 or REM duration; or with 
mPFC volume. As expected (21;22), SWS duration was higher in females than in males even after controlling for 
age and WASO (F1-33=4.5, p<0.05; females: 76.8±27.1 min, males: 47.4±30.2 min).   
 
Effects of SWS duration and power on CSF Aβ42 levels: 
We first examined whether SWS duration correlated with CSF Aβ42 levels. There was a significant inverse 
correlation between CSF Aβ42 and SWS duration (r=-0.35, p<0.05) (Figure 1), %SWS (r=-0.36, p<0.05), total 
SWA in F4 (r=-0.45, p<0.01) (Figure 1), SWA in cycle 1 in F4 (r=-0.41, p<0.05), and SWA in cycle 2 in F4 (r=-
0.38, p<0.05). Similar but weaker inverse correlations were found between CSF Aβ42 and SWA in the C3 channels 
(Table 4) and there were no associations with SWA in the O2 channels. CSF Aβ42 was not correlated with the 
duration of other sleep stages.  Using OLS, the best prediction model for CSF Aβ42 included total SWA in F4, sex 
and ApoE4 status (Table 3).  Based on % increase in R2, total SWA in F4 reduced the variation in Aβ42 by 
116.98%, compared to the model that only included sex and ApoE4. The next best sleep predictors for  CSF Aβ42 
were SWA in cycle 1 in F4, followed by SWA in cycle 2 in F4, which increased the R2 by 98.11% and 69.81%, 
respectively (Table 3).  
 
Effects of SWS continuity in ‘low Aβ42’ and ‘high Aβ42’ groups on CSF Aβ42 levels: 
There were no clinical differences between ‘high’ and ‘low’ Aβ42 groups except for age, which was lower in the 
‘low Aβ42’ (F1-35=4.5, p<0.05; ‘high Aβ42’ group: 70.2±9.0 years, ‘low Aβ42’ group: 63.7±6.3years) (Table 1). 
The cumulative duration probability distribution for SWS was significantly left-shifted in the ‘high Aβ42’ compared 
to ‘low Aβ42’ subjects (p <0.01), indicating that SWS was more fragmented and occurred in shorter bouts in ‘high 
Aβ42’ subjects than in the ‘low Aβ42’ group. Conversely, the cumulative duration probability distribution for 
NREM2 was significantly right-shifted in the ‘high Aβ42’ compared to ‘low Aβ42’ subjects (p <0.01), indicating 
NREM2 sleep was less fragmented and occurred in longer bouts in ‘high Aβ42’ subjects. There were no significant 
differences in the duration probability distribution of NREM1 or REM sleep between groups.  
While the cumulative duration probability distribution reflects sleep continuity across groups, individual measures 
of sleep stage continuity can be represented by stage mean bout length (with longer length reflecting increased sleep 
consolidation) and percent of runs of sleep lasting less than 3 minutes (with a higher percentage reflecting decreased 
sleep consolidation). Based on the results of the survival curve analysis, we examined the correlation between CSF 
Aβ42 levels and measures of NREM2 and SWS continuity. Across all subjects, there were no significant 
correlations between CSF Aβ42 levels and NREM2 continuity variables. On the other hand, we observed a 
significant inverse correlation between CSF Aβ42 levels and SWS mean bout length (rho=-0.37, p <0.05) and a 
significant positive correlation between CSF Aβ42 levels and percent of runs of SWS less than 3 minutes (rho=0.42, 
p=0.01). Using a partial correlation to control for age, we showed a continued significant positive partial correlation 
between CSF Aβ42 levels and percent of runs of SWS less than 3 minutes (rho=0.36, p <0.05), suggesting that 
controlling for age had little effect on the strength of the relationship between these variables. A partial correlation 
controlling for age demonstrated a reduced strength of association between CSF Aβ42 levels and SWS mean bout 
length (rho=-0.31, p=0.069), suggesting that age has some mediating effect on this relationship. 
 
DISCUSSION: 
Understanding the relation between sleep and Aβ might present important opportunities for therapy to slow the 
progression of AD.  Although soluble Aβ42 levels may be influenced by several factors in the elderly, changes in 
sleep common in late-life such as age-dependent loss of SWS and increased incidence of insomnia and sleep apnea 
(24) could lead to relative high brain soluble Aβ42 levels in the stages prior to amyloid deposition. Our findings 
provide a link between diminished SWS duration, continuity, and delta power with high CSF Aβ42 in a normal 
aging group.  
Evidence from both human and animal models suggests that Aβ production is neuronal activity-dependent, 
following a diurnal pattern wherein peak levels occur during periods of activity and decline during sleep (12-14).  
Aβ production is thus postulated to decrease predominantly during SWS due to the decreased neuronal activity 
observed in this sleep stage. In view of our results, a decrease in CSF Aβ42 would occur in periods of sleep with 
high SWA in the frontal lead, although these relationships were also observed in the central electrodes and were 
present in all NREM sleep cycles.  Our current observations are consistent with previous human studies in which 
nadirs in lumbar CSF Aβ42 levels occurred at a point roughly 2/3 of the way through typical TST, after which most 
SWS has occurred and after which sleep is predominated by stages NREM1-2 and REM (3). Attenuation of the Aβ 
diurnal pattern with age may be explained by a relative increase in neuronal activity following disturbed sleep, 
reflecting age-related loss of SWS, which in turn may elevate Aβ levels and promote local amyloid deposition. 
Synaptic downscaling during sleep is thought to be necessary to counter waking activity synaptic potentiation and 
associated growth, which would otherwise exceed available resources of energy and space (25). This synaptic 
homeostasis theory proposes that most downscaling is achieved during SWS. Given that synaptic activity is thought 
to increase CSF Aβ concentrations, and SWS is a stage of sleep where there is a decrease in brain connectivity and a 
global downscaling, SWS may therefore be the stage that is most responsible for the morning after sleep decreases 
in CSF Aβ42 (26). An additional possible mechanism involves sleep’s putative role in the clearance of brain 
metabolites, including Aβ (27). Fragmented SWS would reduce egress of Aβ out of the brain, leaving higher 
concentrations in the brain interstitial fluid that is ultimately reflected in CSF concentrations.  
It bears noting that the functional significance of elevated CSF Aβ42 levels is not established. Although it makes 
intuitive sense that higher concentrations of CSF Aβ42 would foster its aggregation, longitudinal studies of how 
CSF concentrations of Aβ42 change over time, particularly as cognitively normal subjects progress to dementia, has 
not been carefully studied. While mouse models show early increases in Aβ before late decreases (28), there is only 
incidental cross-sectional evidence of elevations in CSF Aβ42 in human studies from familial AD mutation carriers 
(29) and cognitively normal elderly in early pre-symptomatic stages of the disease (30;31) . While it has been 
demonstrated that CSF levels of Aβ42 are about 50%  of control levels when compared to age-matched subjects 
without AD (32), it remains to be determined whether there is a period of elevated CSF Aβ42 in humans prior to 
decline as our data  suggests.  
The interval between polysomnography and CSF collection was of 6.7±7.5 months. Although neither SWS nor CSF 
Aβ42 change markedly over this short duration in normal subjects, we nonetheless recognize this may have 
introduced variability. Additionally, measurement of SWS itself may have been affected by the equipment required 
for its recording. However, most subjects completed home sleep monitoring as part of existing studies prior to in-lab 
polysomnography such that some level of acclimation to the recording equipment was likely.  
Our results cannot define the causal relationship between reduced SWS and high CSF Aβ42.  Although we favor the 
model in which age-dependent long term disruption of SWS promotes higher Aβ42, disturbed sleep may 
alternatively be a consequence of accumulated extracellular Aβ42 early in the progression of AD pathology rather 
than a key event in AD pathogenesis.  The sleep-wake changes described in APP-PS1 mice may be due to induced 
changes in synaptic activity and excitability occurring in brain regions affected by amyloid deposition (33).  In 
humans, a recent study found that individuals diagnosed with AD had fewer neurons than controls in the 
intermediate nucleus, a brain region that is thought to promote sleep by inhibiting wake-promoting brain regions 
(34).  Additionally, the impairment in sleep-dependent declarative memory consolidation observed in subjects with 
high amyloid load was found to be mediated by the loss in frontal SWA (35), suggesting that changes in SWS lie 
downstream of Aβ42 deposition. Because these observations are not mutually exclusive of an effect of SWS on 
soluble Aβ42, the interaction between a loss of SWS and Aβ42 may perpetuate a positive feedforward cycle. 
Amyloid deposition may damage neurons responsible for generating slow waves, further disturbing sleep and 
elevating Aβ42 levels during wakefulness (13) until a certain degree of amyloid burden is reached that captures and 
prevents the transport of soluble Aβ42 from the brain to the lumbar space CSF (36). 
Irrespective of an effect of Aβ42 on sleep, the effect of SWS on soluble Aβ42 is noteworthy because it raises the 
possibility for new disease-modifying drug targets that slow AD progression. The mechanism by which SWS can be 
modified may take many forms. In older subjects with SDB, treatment with CPAP improves sleep architecture 
including increased SWS (37). In older subjects without SDB, transcranial magnetic stimulation (38) and existing 
medications (39;40) may increase or trigger SWS and reduce Aβ42 production. Whether such interventions in older 
subjects affect Aβ42 metabolism and/or progression of clinical AD remains to be tested, but our current findings 
support further investigation.  
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6. Figure Legends and Tables 
 
Table 1. Sociodemographic, Clinical and CSF Data of Study Group 
     
 Global (n=36) High Aβ42 (n=18) Low Aβ42 (n=18) P-Value High vs. 
Low Aβ42 group 
Age, mean (SD), 
years 
66.8 (8.2) 69.9 (8.6) 63.6 (6.5) 0.02 
Male Sex, No. (%) 17(47.2%) 11(61.1%) 6 (33.3%) 0.10 
BMI, mean (SD), 
kg/m2 
25.8 (3.7) 26.3 (3.6) 25.2 (3.8) 0.39 
Education, mean 
(SD), years 




0 0 0  
MMSE, mean (SD) 29.3 (1.1) 29.1 (1.1) 29.4 (1.1) 0.46 
Hypertension, No. 
(%) 
11(27.8) 7(38.9) 4(22.2) 0.28 
Cardiovascular 
disease, No. (%) 
1(2.8) 1(5.6) 0(0) 0.31 
Diabetes, No. (%) 1(2.8) 1(5.6)  0(0) 0.31 
Thyroid, No. (%) 7(19.4) 3(16.7) 4(22.2) 0.67 












Aβ42, median (IQR), 
pg/mL 
539.7 (269.8) 729.8 (359.3) 474.8 (108.9) p<0.001 
P-Tau, median 
(IQR), pg/mL 
38.7 (19.3) 40.8 (14.5) 33.2 (17.7) 0.27 
T-Tau, median 
(IQR), pg/mL 
232.0 (13.4) 260.0 (158.9) 189.7 (140.0) 0.10 
 
 Table 2. Slow Wave Sleep Characteristics of Study Group 
 Global High Aβ42 Low Aβ42 P-value 


















Mean N3 runs, 
median (IQR) 
 1.8 (1.1) 2.4 (1.5) 0.04* 
% N3 runs ≤ 3min, 
median (IQR) 
 51.4 (47.5) 32.2 (18.1) 0.02* 
% N3 runs ≥ 5min, 
median (IQR) 
 37.9 (57.9) 59.9 (22) 0.03* 
 
 
Table 3. Linear Regression Analysis 
 Table 4. Pearson Correlation with LnAβ42 
 R P-Value 
LnSWAfullnight_F4 -0.45 0.005 
LnSWAcycle1_F4 -0.41 0.01 
LnSWAcycle2_F4 -0.38 0.02 
LnSWAfullnight_C3 -0.38 0.02 
Percent time spent in SWS -0.36 0.03 
SWS duration -0.35 0.03 
LnSWAcycle1_C3 -0.34 0.04 
LnSWAcycle2_C3 -0.34 0.04 
ApoE4 status -0.23 0.18 
Sex -0.25 0.14 
Age 0.23 0.16 



































ApoE4 status -0.15 -1.24 0.22 
sex -0.17 -1.11 0.14 
LnSWAfullnightF4 -0.38 -2.25 0.03 0.23 0.16 116.98 3.16 0.04 
LnSWAcycle1F4 -0.40 -2.09 0.05 0.21 0.14 98.11 2.89 0.05 
LnSWAcycle2F4 -0.30 -1.75 0.09 0.18 0.10 69.81 2.41 0.09 
LnSWAfullnightC3 -0.28 -1.56 0.13 0.17 0.09 60.38 2.17 0.11 
LnSWAcycle1C3 -0.27 -1.35 0.19 0.15 0.08 45.28 1.95 0.14 
LnSWAcycle2C3 -0.24 -1.34 0.19 0.15 0.07 45.28 1.93 0.14 
% Time SWS -0.26 -1.33 0.19 0.15 0.07 44.34 1.92 0.15 
SWS Duration -0.25 -1.32 0.20 0.15 0.07 43.40 1.91 0.15 
Figure 1. Scatter Plots of Natural Log of Aβ42 and F4 Slow Wave Activity (Full Night) and Slow Wave Sleep 
Duration 
 
